Home › Companies › ARCUS BIOSCIENCES INC. › 2023-2024

ARCUS BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ARCUS BIOSCIENCES INC.’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated October 13, 2026.

5Ballot items
213Asset managers
1,449Fund votes
June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 5 items on ARCUS BIOSCIENCES INC.’s Form 8-K, filed June 6, 2024: 5 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided · This season’s results screens

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARCUS BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARCUS BIOSCIENCES INC.

These tallies are ARCUS BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARCUS BIOSCIENCES INC. — official shareholder meeting results, meeting held June 6, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Kathryn Falberg	66,352,943	--	--	10,783,215	8,822,193	86%	Not verified	—
Elect Director: Linda Higgins	61,694,808	--	--	15,441,350	8,822,193	80%	Not verified	—
Elect Director: Terry Rosen	67,130,968	--	--	10,005,190	8,822,193	87%	Not verified	—
2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024	84,330,586	1,242,487	385,278	--	--	99%	Not verified	—
3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement	74,230,276	2,863,260	42,662	--	8,822,193	96%	Not verified	—

Source: ARCUS BIOSCIENCES INC., Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.

How asset managers voted at the ARCUS BIOSCIENCES INC. 2023-2024 meeting

Each item below shows how the 213 asset managers that disclosed a ARCUS BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Kathryn Falberg

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%

FOR: 66,352,943WITHHELD: 10,783,215

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: Election of Directors: Kathryn Falberg

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kathryn Falberg”): 66,352,943 for, 10,783,215 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 20,673,016 for, 3,669,665 withheld.

FORWITHHOLD

FOR: 20,673,016WITHHOLD: 3,669,665

Largest asset managers voting on “Election of Directors: Kathryn Falberg” at ARCUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Withheld	Vote
Fidelity	5,806,946	37,382	For
BlackRock	5,234,776	0	For
Vanguard	4,693,497	0	For
State Street	3,475,333	50,039	For
Dimensional	0	1,184,566	Withhold
AB DISCOVERY GROWTH FUND, INC.	0	551,175	Withhold
Charles Schwab	468,738	0	For
Delaware/Macquarie	0	379,100	Withhold
Equitable	82,999	253,908	Mixed
MUTUAL FUND SERIES TRUST	240,000	0	For
Direxion Shares ETF Trust	0	175,280	Withhold
Columbia Threadneedle	155,787	0	For
Victory Capital	0	139,727	Withhold
Jackson National	0	136,438	Withhold
TIAA	125,290	0	For
ALPS ETF Trust	0	64,090	Withhold
BNY Mellon	0	62,055	Withhold
ProShares	0	61,739	Withhold
Principal	0	60,715	Withhold
Invesco	58,086	0	For
American Century	0	57,898	Withhold
Prudential/PGIM	56,223	0	For
MFS	0	56,174	Withhold
Lincoln Financial	44,400	8,738	Mixed
Thrivent	0	46,429	Withhold

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

2. Elect Director: Linda Higgins

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD

FOR: 61,694,808WITHHELD: 15,441,350

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: Election of Directors: Linda Higgins, Ph.D.

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Linda Higgins”): 61,694,808 for, 15,441,350 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 17,051,197 for, 7,291,484 withheld.

FORWITHHOLD

FOR: 17,051,197WITHHOLD: 7,291,484

Largest asset managers voting on “Election of Directors: Linda Higgins, Ph.D.” at ARCUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Withheld	Vote
Fidelity	5,806,946	37,382	For
BlackRock	5,234,776	0	For
Vanguard	4,693,497	0	For
State Street	35,943	3,489,429	Withhold
Dimensional	0	1,184,566	Withhold
AB DISCOVERY GROWTH FUND, INC.	0	551,175	Withhold
Charles Schwab	468,738	0	For
Delaware/Macquarie	0	379,100	Withhold
Equitable	82,999	253,908	Mixed
MUTUAL FUND SERIES TRUST	240,000	0	For
Direxion Shares ETF Trust	0	175,280	Withhold
Columbia Threadneedle	155,787	0	For
Victory Capital	0	139,727	Withhold
Jackson National	0	136,438	Withhold
TIAA	125,290	0	For
ALPS ETF Trust	0	64,090	Withhold
BNY Mellon	0	62,055	Withhold
ProShares	0	61,739	Withhold
Principal	0	60,715	Withhold
Invesco	0	58,086	Withhold
American Century	0	57,898	Withhold
Prudential/PGIM	0	56,223	Withhold
MFS	0	56,174	Withhold
Lincoln Financial	0	53,138	Withhold
Thrivent	0	46,429	Withhold

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

3. Elect Director: Terry Rosen

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%

FOR: 67,130,968WITHHELD: 10,005,190

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: Election of Directors: Terry Rosen, Ph.D.

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Terry Rosen”): 67,130,968 for, 10,005,190 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 21,500,622 for, 2,842,059 withheld.

FOR

FOR: 21,500,622WITHHOLD: 2,842,059

Largest asset managers voting on “Election of Directors: Terry Rosen, Ph.D.” at ARCUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Withheld	Vote
Fidelity	5,843,023	1,305	For
BlackRock	5,234,776	0	For
Vanguard	4,693,497	0	For
State Street	3,475,333	50,039	For
Dimensional	0	1,184,566	Withhold
AB DISCOVERY GROWTH FUND, INC.	551,175	0	For
Charles Schwab	468,738	0	For
Delaware/Macquarie	0	379,100	Withhold
Equitable	336,907	0	For
MUTUAL FUND SERIES TRUST	240,000	0	For
Direxion Shares ETF Trust	0	175,280	Withhold
Columbia Threadneedle	155,787	0	For
Victory Capital	0	139,727	Withhold
Jackson National	0	136,438	Withhold
TIAA	125,290	0	For
ALPS ETF Trust	0	64,090	Withhold
BNY Mellon	0	62,055	Withhold
ProShares	0	61,739	Withhold
Principal	0	60,715	Withhold
Invesco	58,086	0	For
American Century	0	57,898	Withhold
Prudential/PGIM	0	56,223	Withhold
MFS	56,174	0	For
Lincoln Financial	44,400	8,738	Mixed
Thrivent	0	46,429	Withhold

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

4. 3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in…

Outcome not verified Fund totals may overlapCOMPENSATIONReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 74,230,276AGAINST: 2,863,260

Details: description as filed, official tally, votes by 213 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.

ARCUS BIOSCIENCES INC.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 74,230,276 for, 2,863,260 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 76 asset managers voting on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclose” at ARCUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	5,844,328	0	For
BlackRock	5,234,776	0	For
Vanguard	4,693,497	0	For
State Street	3,510,918	14,454	For
Dimensional	1,184,566	0	For
AB DISCOVERY GROWTH FUND, INC.	551,175	0	For
Charles Schwab	468,738	0	For
Delaware/Macquarie	379,100	0	For
Equitable	336,907	0	For
MUTUAL FUND SERIES TRUST	240,000	0	For
Direxion Shares ETF Trust	175,280	0	For
Columbia Threadneedle	155,787	0	For
Victory Capital	139,727	0	For
Jackson National	136,438	0	For
TIAA	125,290	0	For
ALPS ETF Trust	64,090	0	For
BNY Mellon	62,055	0	For
ProShares	61,739	0	For
Principal	60,715	0	For
Invesco	0	58,086	Against
American Century	0	57,898	Against
Prudential/PGIM	56,223	0	For
MFS	0	56,174	Against
Lincoln Financial	53,138	0	For
Thrivent	46,429	0	For

Fund voting reports, all 76 managers: 23,981,570 for, 350,897 against, 10,214 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 160 asset managers voting on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclose” at ARCUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	4,708,631	0	For
State Street	4,484,507	30,622	For
Woodline Partners LP	2,498,994	0	For
Point72	1,759,101	0	For
BlackRock	1,327,536	7,194	For
GEODE CAPITAL MANAGEMENT, LLC	1,151,010	0	For
AMERIPRISE FINANCIAL INC	1,053,152	0	For
AllianceBernstein	990,799	0	For
SUVRETTA CAPITAL MANAGEMENT, LLC	957,299	0	For
Decheng Capital LLC	869,790	0	For
BNP Paribas Asset Management Holding S.A.	0	732,497	Against
Laurion Capital Management LP	502,123	0	For
Charles Schwab	493,823	0	For
Northern Trust	415,764	2,016	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	379,100	0	For
PRINCIPAL GLOBAL INVESTORS	288,392	0	For
MELLON INVESTMENTS Corp	283,746	0	For
NORDEA INVESTMENT MANAGEMENT AB	0	259,372	Against
UBS	19	233,242	Against
DAFNA Capital Management LLC	231,715	0	For
Two Sigma	223,044	0	For
Granahan Investment Management, LLC	213,023	0	For
PLATINUM INVESTMENT MANAGEMENT LTD	204,398	0	For
PANAGORA ASSET MANAGEMENT INC	179,675	0	For
Dimensional	176,538	0	For

Institutional-manager reports, all 160 managers: 25,036,677 for, 2,033,215 against, 175 abstained, 2,930 not voted. Showing the 25 largest; see all in the interactive database.

5. 2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 84,330,586AGAINST: 1,242,487

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

ARCUS BIOSCIENCES INC.’s own tally for this item (“2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December”): 84,330,586 for, 1,242,487 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 23,785,827 for, 546,640 against, 10,214 abstained.

FOR

FOR: 23,785,827AGAINST: 546,640ABSTAIN: 10,214

Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDE” at ARCUS BIOSCIENCES INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	5,844,328	0	For
BlackRock	5,234,776	0	For
Vanguard	4,693,497	0	For
State Street	3,520,086	5,286	For
Dimensional	1,184,566	0	For
AB DISCOVERY GROWTH FUND, INC.	551,175	0	For
Charles Schwab	0	468,738	Against
Delaware/Macquarie	379,100	0	For
Equitable	336,907	0	For
MUTUAL FUND SERIES TRUST	240,000	0	For
Direxion Shares ETF Trust	175,280	0	For
Columbia Threadneedle	155,787	0	For
Victory Capital	139,727	0	For
Jackson National	136,438	0	For
TIAA	125,290	0	For
ALPS ETF Trust	64,090	0	For
BNY Mellon	62,055	0	For
ProShares	61,739	0	For
Principal	60,715	0	For
Invesco	58,086	0	For
American Century	57,898	0	For
Prudential/PGIM	56,223	0	For
MFS	56,174	0	For
Lincoln Financial	53,138	0	For
Thrivent	46,429	0	For

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

Largest ARCUS BIOSCIENCES INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 90,900,000 shares outstanding at the time of that meeting.

Fund voting reports: top ARCUS BIOSCIENCES INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Fidelity	6.43%
2	BlackRock	5.76%
3	Vanguard	5.16%
4	State Street	3.88%
5	Dimensional	1.30%
6	AB DISCOVERY GROWTH FUND, INC.	0.61%
7	Charles Schwab	0.52%
8	Delaware/Macquarie	0.42%
9	Equitable	0.37%
10	MUTUAL FUND SERIES TRUST	0.26%

Institutional-manager reports: top ARCUS BIOSCIENCES INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Fidelity	5.18%
2	State Street	4.97%
3	Woodline Partners LP	2.75%
4	Point72	1.94%
5	BlackRock	1.47%
6	GEODE CAPITAL MANAGEMENT, LLC	1.27%
7	AMERIPRISE FINANCIAL INC	1.16%
8	AllianceBernstein	1.09%
9	SUVRETTA CAPITAL MANAGEMENT, LLC	1.05%
10	Decheng Capital LLC	0.96%

Reported ARCUS BIOSCIENCES INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ARCUS BIOSCIENCES INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Gilead Sciences, Inc.	33.07%	DEF14A
BlackRock, Inc.	11.04%	DEF14A
Vanguard Group	7.29%	13F
State Street	5.40%	13F
FMR LLC	5.20%	DEF14A
Terry Rosen, Ph.D.	4.17%	13D
Point72	2.11%	13F
Dimensional Fund Advisors	1.78%	13F
Morgan Stanley	1.69%	13F
Juan Carlos Jaen, Ph.D.	1.56%	DEF14A

Percentages above are of 90,900,000 shares outstanding, as reported by ARCUS BIOSCIENCES INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARCUS BIOSCIENCES INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 13, 2026; a live search always shows the current data.

At ARCUS BIOSCIENCES INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 213 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,449 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ARCUS BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.

ARCUS BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.